We compared patients who received placebo on their first visit (Placebo-1st) and patients who received placebo on their second visit (Placebo-2nd, Table S1 ). There was no significant difference between the two Parkinson's disease (PD) sub-groups, or between controls and Placebo-1st (chi-squared or two-sample t-tests as appropriate, p < 0.05 uncorrected for multiple comparison). Stop-Signal Reaction Time (SSRT) and NoGo error rates were larger in Placebo2nd than in controls. However, the direction of effect suggests that the difference is not driven by practice, since the absolute reaction times and error rates were in the direction of worse performance.
. Comparisons between patients who received placebo on their first visit and patients who received placebo on their second visit (means, standard deviations and group differences) 
Additional Region of Interest (ROI) Analysis

Effects of Atomoxetine in Other Brain Areas
The NoGo and SSRT tasks were associated with widespread activations beyond the right inferior frontal gyrus (RIFG), in our study and previous reports. We therefore investigated post hoc the effects of atomoxetine on other brain areas including the left inferior frontal gyrus (LIFG), supplementary motor area (SMA), striatum and thalamus.
The LIFG and SMA ROIs were defined as the intersection of the AAL-based anatomical LIFG or SMA and the SS > Go activation in controls (one-sample t-test, voxel-level p < 0.001 uncorrected, cluster-level p < 0.05 FWE-corrected). These ROIs are therefore independent of the patient data with which we sought an effect of drug.
The striatum and thalamus ROIs were anatomically defined because neither region was observed for SS > Go in controls at our standard threshold in this study (Table S2) There was no effect of atomoxetine in the LIFG, SMA or striatum. However, the thalamus showed a drug-by-UPDRS interaction (F = 5.79, p < 0.05) and a drug-by-age interaction (F = 12.12, p < 0.005; Figure S1 ). This indicates that atomoxetine modulated the stop-related thalamic activation in advanced disease and in older patients. Figure S1 . Effects of atomoxetine in the thalamus.
Effect of Atomoxetine Concentration
The plasma concentration is a factor that could influence the impact of atomoxetine on behavior and brain activity. In the main analysis, we used multiple regression models to examine the factors that influence performance and activation. In the presence of multiple variables, which partially correlate, the multiple regression approach is preferred over a set of simple correlations. Using these multiple regression models, we identified the UPDRS motor, age and frontostriatal connectivity, but not the plasma concentration, as explanatory variables for regional frontal activation (main text page 11, Figure 1 
